Researchers, Officials Dealing with VA Problems in L.A.

Studies are slowly restarting at the Veterans Administration Greater Los Angeles Healthcare System (VAGLAHS) after an unprecedented suspension of research last March 26.1 Investigators, meanwhile, are dealing with the fallout, and many are waiting to learn the fates of their protocols. They're also struggling still to understand why such drastic action was taken because of administrative failures. "We're all ... amazed this could happen, and I think all of us feel we're being blamed for what is

Written byA. J. S. Rayl
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

Studies are slowly restarting at the Veterans Administration Greater Los Angeles Healthcare System (VAGLAHS) after an unprecedented suspension of research last March 26.1 Investigators, meanwhile, are dealing with the fallout, and many are waiting to learn the fates of their protocols. They're also struggling still to understand why such drastic action was taken because of administrative failures. "We're all ... amazed this could happen, and I think all of us feel we're being blamed for what is probably an administrative oversight ...," says George Sachs, who heads the membrane biology laboratory at the West LA Healthcare Center.

The story emerging is one of missing memos, a lack of communication, lack of follow-up, and lack of resources and support. VAGLAHS was hit with two suspensions last March--one from the VA headquarters and another from the National Institutes of Health's Office for Protection from Research Risks (OPRR), which terminated its umbrella contract ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies